BUFFALO, N.Y. and IRVINE, Calif. – Empire Genomics and BioDot have partnered to introduce the BDot Probe Line, a series of pre-optimized FISH probe panels and controls specifically designed for automated hematology diagnostics. This collaboration addresses a longstanding industry challenge by delivering ready-to-use reagents validated for the BioDot CellWriter™ S platform.
Streamlining Hematologic Testing
The initial product release targets key hematologic malignancies including multiple myeloma, leukemias, and myelodysplastic syndromes. The system eliminates traditional probe optimization steps, reducing technician workload and accelerating diagnostic turnaround times. Proprietary control probes further simplify laboratory validation processes.
Industry Impact and Benefits
“By combining our molecular expertise with BioDot’s automation platform, we’re delivering a complete solution that improves both efficiency and consistency,” said John Steel of Empire Genomics. Early adopters report superior signal quality and rapid implementation, with the solution arriving as new FDA regulations emphasize standardized testing protocols.
Strategic Partnership Potential
BioDot’s Debbie Bowers revealed this launch represents just the first phase of collaboration, with plans to expand the BDot line with additional disease panels and enhanced automation features. The partnership aims to redefine FISH diagnostics through integrated hardware and chemistry solutions.
Future Development Roadmap
The companies will continue co-developing tools for workflow automation, data traceability, and comprehensive reporting. This innovation comes as molecular pathology labs increasingly seek turnkey solutions to meet growing testing demands while maintaining regulatory compliance.
Related Topics: